Future cardiology最新文献_第9页

Evaluating the AltaValve as a novel method for transcatheter mitral valve replacement. 评价AltaValve作为经导管二尖瓣置换术的新方法。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-09 DOI: 10.1080/14796678.2025.2499352

Pablo Vidal-Calés, Pedro L Cepas-Guillén, Juan H Del Portillo, Josep Rodés-Cabau

{"title":"Evaluating the AltaValve as a novel method for transcatheter mitral valve replacement.","authors":"Pablo Vidal-Calés, Pedro L Cepas-Guillén, Juan H Del Portillo, Josep Rodés-Cabau","doi":"10.1080/14796678.2025.2499352","DOIUrl":"10.1080/14796678.2025.2499352","url":null,"abstract":"Mitral regurgitation (MR) is the most common heart valve disease, and severe MR is associated with a poor prognosis if left untreated. Although surgical repair or replacement constitutes the standard therapy when indicated, many high-risk patients are considered ineligible for surgery. Transcatheter mitral valve replacement (TMVR) offers a less invasive alternative to conventional surgery and may also overcome some of the limitations of percutaneous repair techniques. Currently, multiple TMVR devices are undergoing clinical evaluation, showing promising results. However, challenges mainly related to the complex mitral valve anatomy along with the interaction with the left ventricular outflow tract (LVOT) have resulted in high screen failure rates among TMVR candidates. The AltaValve System features a supra-annular design, ensuring secure fixation in the left atrium above the native mitral valve annulus without anchoring mechanisms that could interfere with the left ventricle (LV). These distinctive attributes aim to address the existing TMVR limitations across a broad patient population and help to avoid complications such as LVOT obstruction, LV damage, and/or prosthesis embolization. Initial safety and feasibility data are encouraging, but a larger cohort of patients with longer follow-up will be essential to confirm the safety and efficacy of the AltaValve system.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"455-466"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12517466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000013","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A novel familial pathogenic desmoplakin (DSP) gene mutation (c.4751_4752del) presenting as "hot-phase" left-dominant arrhythmogenic cardiomyopathy. 一种新的家族致病性desmoplakin （DSP）基因突变（c.4751_4752del）表现为“热期”左显性心律失常性心肌病。

IF 1

Future cardiology Pub Date : 2025-06-01 Epub Date: 2025-05-05 DOI: 10.1080/14796678.2025.2500835

Victoria Fanucci, Dhaval Chauhan, Nita Ray Chaudhuri, Hemal M Nayak, Utkarsh Kohli

{"title":"A novel familial pathogenic desmoplakin (DSP) gene mutation (c.4751_4752del) presenting as \"hot-phase\" left-dominant arrhythmogenic cardiomyopathy.","authors":"Victoria Fanucci, Dhaval Chauhan, Nita Ray Chaudhuri, Hemal M Nayak, Utkarsh Kohli","doi":"10.1080/14796678.2025.2500835","DOIUrl":"10.1080/14796678.2025.2500835","url":null,"abstract":"Desmoplakin, encoded by DSP (Online Mendelian Inheritance in Man [OMIM]: 125647), is a central component of desmosomes. Mutations in DSP have been implicated in the development of arrhythmogenic cardiomyopathy (ACM) and other cutaneous conditions. We report on a rare, myocarditis-like presentation of left-dominant arrhythmogenic cardiomyopathy (LDACM) in a 16-year-old girl with a novel familial frame-shift DSP c.4751_4752del (p.Ala1584Valfs *42, rs2113694794) mutation. The patient developed sustained ventricular tachycardia, which was controlled with amiodarone and required implantation of a dual-chamber transvenous defibrillator for sudden cardiac death (SCD) prophylaxis as her 5-year risk of adverse outcomes was estimated to be 25%. The findings in this patient highlight the importance of including ACM in the differential diagnosis for patients presenting with myocarditis, given that the sequelae of ACM include early development of heart failure (HF), ventricular arrhythmia (VA), and SCD.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"473-478"},"PeriodicalIF":1.0,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12506742/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010371","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cardiomyopathy genetic testing: insights into demographics, counseling, and cascade screening. 心肌病基因检测：洞察人口统计学，咨询，和级联筛选。

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-04-09 DOI: 10.1080/14796678.2025.2484128

Quan M Bui, Elizabeth Silver, Alessia Argiro, Sarah Murray, Lauren Korty, Jorge Silva Enciso, Marcus A Urey, Neil C Chi, Kimberly N Hong, Eric D Adler

{"title":"Cardiomyopathy genetic testing: insights into demographics, counseling, and cascade screening.","authors":"Quan M Bui, Elizabeth Silver, Alessia Argiro, Sarah Murray, Lauren Korty, Jorge Silva Enciso, Marcus A Urey, Neil C Chi, Kimberly N Hong, Eric D Adler","doi":"10.1080/14796678.2025.2484128","DOIUrl":"10.1080/14796678.2025.2484128","url":null,"abstract":"Background: Genetic testing (GT) is clinically indicated for patients with suspected inherited cardiomyopathy (CM) but is underutilized.Methods: This single-center study included patients with CM who underwent outpatient GT from 2018 to 2023. Data were collected from the medical record.Results: A total of 306 patients were included, with a mean age of 62 years and were predominantly male (63%) and White (59%). Heart failure (92%) cardiologists were most likely to order testing, followed by general cardiology (5%) providers at tertiary hospital clinics (89%). The most common phenotypes were hypertrophic (30%), amyloid (29%) and dilated (21%). There were 17% of patients who had a positive test and 53% of patients who had a variant of uncertain significance. Patients with a positive family history had a significantly higher positive yield compared to those without (p < 0.01). Genetic counselors were underutilized (17%). For patients who had a positive test result, only 40% had cascade screening.Conclusions: Outpatient GT for CM was primarily ordered by heart failure cardiologists in tertiary hospital clinics. Cascade screening was low, which may reflect the limited use of genetic counselors. Further research is needed to understand implementation barriers to GT.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"359-364"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143810969","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Risk of cardiovascular disease in people with narcolepsy: a plain language summary of publication. 发作性睡病患者的心血管疾病风险：出版物的简明语言摘要。

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-04-02 DOI: 10.1080/14796678.2025.2482383

Jed Black, Rorey Smith, Elizabeth C Dabrowski, Ben Taylor, Virend K Somers

引用次数: 0

Preventing cerebrovascular events in patients undergoing TAVR: the current and future landscape. 预防TAVR患者的脑血管事件：当前和未来的前景。

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-03-31 DOI: 10.1080/14796678.2025.2484961

Saadullah H Ahmed, Amit N Vora, Tayyab Shah, Alexandra J Lansky

引用次数: 0

Current and future role of biomarkers in the monitoring and prognosis of coronary artery disease. 生物标志物在冠状动脉疾病监测和预后中的作用

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-03-10 DOI: 10.1080/14796678.2025.2477947

Vikrant Rai

引用次数: 0

Real-world evidence comparing oral anticoagulants for NVAF in Europe: a systematic review and network meta-analysis. 比较欧洲口服抗凝剂治疗非瓣瓣性房颤的真实证据：系统回顾和网络荟萃分析。

IF 1

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-04-02 DOI: 10.1080/14796678.2025.2484119

Allie Cichewicz, Shantanu Jawla, Priccila Zuchinali, Morodoluwa Akin-Fajiye, Daniela Massierer, Italo Porto, Xavier Garcia-Moll

{"title":"Real-world evidence comparing oral anticoagulants for NVAF in Europe: a systematic review and network meta-analysis.","authors":"Allie Cichewicz, Shantanu Jawla, Priccila Zuchinali, Morodoluwa Akin-Fajiye, Daniela Massierer, Italo Porto, Xavier Garcia-Moll","doi":"10.1080/14796678.2025.2484119","DOIUrl":"10.1080/14796678.2025.2484119","url":null,"abstract":"Aim: Atrial fibrillation is the most commonly sustained cardiac arrhythmia, increasing the risk of stroke and systemic embolic events. This systematic review and network meta-analysis (NMA) aimed to compare real-world evidence (RWE) on the effectiveness and safety of edoxaban with other direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs) in patients with non-valvular atrial fibrillation (NVAF) in Europe.Materials & methods: Searches from January 2013 to December 2022 identified comparative observational studies assessing effectiveness/safety outcomes in patients with NVAF. Bayesian NMA estimated comparative effectiveness/safety of edoxaban with other DOACs and VKAs.Results: The review identified 57 studies analyzing data from 24 unique databases; 33 studies were included in the base-case analyses. DOACs showed benefit over VKAs for most outcomes, of which major bleeding and all-cause mortality were most commonly reported. Edoxaban demonstrated a comparable effectiveness/safety profile to other DOACs and significantly reduced risk of major bleeding (hazard ratio [95% credible interval]: 0.67 [0.54, 0.84]) and intracranial hemorrhage (0.69 [0.51, 0.94]) versus rivaroxaban.Conclusion: This NMA provides valuable insights into the real-world effectiveness and safety of DOACs and VKAs in Europe, supporting clinical decision-making and adding to the existing evidence base from clinical trials.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"371-390"},"PeriodicalIF":1.0,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026226/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143763716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Do gender differences persist in ICD implantation in patients with acute on chronic heart failure? 急慢性心力衰竭患者ICD植入是否存在性别差异？

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-03-30 DOI: 10.1080/14796678.2025.2484958

Jude ElSaygh, Laura Bradel, Kevin Pink, Lu Chen, Jonathan Arnedo, Bharath Reddy, Brian Wong, Jeremy Berman, Stephen J Peterson, Wilber S Aronow, Gioia Turitto

{"title":"Do gender differences persist in ICD implantation in patients with acute on chronic heart failure?","authors":"Jude ElSaygh, Laura Bradel, Kevin Pink, Lu Chen, Jonathan Arnedo, Bharath Reddy, Brian Wong, Jeremy Berman, Stephen J Peterson, Wilber S Aronow, Gioia Turitto","doi":"10.1080/14796678.2025.2484958","DOIUrl":"10.1080/14796678.2025.2484958","url":null,"abstract":"Background: Implantable Cardiac Defibrillators (ICDs) prolong survival in patients with heart failure with reduced ejection fraction (HFrEF). Despite strong data suggesting their benefit, there is concern for disparities related to ICD implantation rates.Methods: A retrospective analysis of 551 patients admitted to a single tertiary institution from June 2020 to May 2023, who met the guideline criteria for ICD implantation for primary prevention of sudden cardiac death, was carried out.Results: Our population constituted of 56% African Americans, 20% Caucasians, 1% Asians and 2% Native Americans. Of those patients, 47% (157/337) of males and 33% (71/213) of females underwent ICD implantation before discharge, creating a statistically significant gender difference at p = 0.007. Patients aged 50 or greater (218/509) were more likely to receive an ICD compared to younger patients (10/41) at p = 0.000. Of those offered an ICD, 46% deferred to outpatient, 30% refused, and 8% of patient had history of noncompliance, were medically unstable, or were undecided.Conclusion: Females and younger patients were less likely to have an ICD at discharge. Despite strong recommendations for ICD implantation in eligible patients, most patients did not receive an ICD. This study showcases the limited access to care and highlights potential avenues of improvement.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"365-370"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026163/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143752199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Observational protocol on neuropsychological disorders in cardiovascular disease for holistic prevention and treatment. 心血管疾病神经心理障碍的整体防治观察方案。

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-03-21 DOI: 10.1080/14796678.2025.2483155

Irene Cappadona, Augusto Ielo, Maria Pagano, Anna Anselmo, Giuseppe Micali, Fabio Mauro Giambò, Antonio Duca, Piercataldo D'Aleo, Daniela Costanzo, Giuseppa Carcione, Claudio Dispenzieri, Francesco Speciale, Placido Bramanti, Alessia Bramanti, Marina Garofano, Francesco Corallo

{"title":"Observational protocol on neuropsychological disorders in cardiovascular disease for holistic prevention and treatment.","authors":"Irene Cappadona, Augusto Ielo, Maria Pagano, Anna Anselmo, Giuseppe Micali, Fabio Mauro Giambò, Antonio Duca, Piercataldo D'Aleo, Daniela Costanzo, Giuseppa Carcione, Claudio Dispenzieri, Francesco Speciale, Placido Bramanti, Alessia Bramanti, Marina Garofano, Francesco Corallo","doi":"10.1080/14796678.2025.2483155","DOIUrl":"10.1080/14796678.2025.2483155","url":null,"abstract":"Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in the world. In view of the close correlation between the functions of the body, which cannot be examined in a piecemeal manner but as an integrated system, a holistic approach allows for a comprehensive assessment of the patient. Our study aims to (i) examine the connection between CVD and cognitive deficits; (ii) examine the presence of anxiety and depression; (iii) evaluate the presence of dysphagia, pneumophonic coordination disorders, respiratory and sleep disorders; (iv) analyze the impact of CVD on the caregiver; and (v) evaluate the effectiveness of psychoeducational intervention. At least 218 patients will participate in the survey. At T0, they will undergo neuropsychological, psychological and associated clinical condition assessment through standardized tests. In addition, at least one psychoeducation meeting will be held. After 6 months (T1), the same tests will be repeated, and the effectiveness of psychoeducation will be evaluated. Assessment of associated disorders will provide a comprehensive view of the patient. In addition, it will be observed how psychoeducational intervention can make changes on general well-being. Comprehensive, multi-step observation allows for identification of risk factors, tailoring of treatment, and prevention of future complications.Clinical Trial Registration: registered on Clinicaltrials.gov (ID: NCT06413823).","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"349-358"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143673824","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Left atrial appendage occlusion in atrial fibrillation: shaping the future of stroke prevention. 房颤左心耳闭塞：塑造卒中预防的未来。

IF 1.6

Future cardiology Pub Date : 2025-05-01 Epub Date: 2025-03-26 DOI: 10.1080/14796678.2025.2484964

Andreas Mitsis, Christos Eftychiou, Athanasios Samaras, Apostolos Tzikas, Nikolaos Fragakis, George Kassimis

{"title":"Left atrial appendage occlusion in atrial fibrillation: shaping the future of stroke prevention.","authors":"Andreas Mitsis, Christos Eftychiou, Athanasios Samaras, Apostolos Tzikas, Nikolaos Fragakis, George Kassimis","doi":"10.1080/14796678.2025.2484964","DOIUrl":"10.1080/14796678.2025.2484964","url":null,"abstract":"Atrial fibrillation (AF) is the most common cardiac arrhythmia, significantly increasing the risk of thromboembolic events, particularly ischemic stroke. The left atrial appendage (LAA) is the predominant site of thrombus formation in patients with AF, making it a crucial target for stroke prevention strategies. Left atrial appendage occlusion (LAAO) has emerged as an important therapeutic alternative to oral anticoagulation, particularly in patients with contraindications to long-term anticoagulant therapy. This review examines the role of LAAO in AF management, discussing current indications, patient selection, procedural techniques, and clinical outcomes. We also explore the latest evidence from major clinical trials and real-world studies, highlighting the efficacy and safety of LAAO compared to standard anticoagulation. Additionally, we consider the unresolved questions and the potential future directions for this intervention, including emerging technologies and the integration of LAAO into broader AF management protocols. Our review underscores the growing importance of LAAO in reducing thromboembolic risk in AF patients, particularly those unable to tolerate traditional anticoagulation, and offers insights into the ongoing evolution of this treatment modality in clinical practice.","PeriodicalId":12589,"journal":{"name":"Future cardiology","volume":" ","pages":"391-404"},"PeriodicalIF":1.6,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12026124/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143709558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0